Details

Project TitleTargeting FKBP52 for Cancer Treatment
Track Code2014-009
Short Description

The University of Texas at El Paso seeks a partner for licensing a prostate cancer treatment that targets the FKBP52 cochaperone, a critical protein for androgen receptor signaling.

Abstract

This invention is a novel drug molecule that binds directly to the FKBP52 protein to disrupt both FKBP52 and beta-catenin regulation of AR activity leading to the inhibition of androgen-dependent gene expression and androgen-dependent prostate cancer cell proliferation. In addition to the inhibition of FKBP52 and beta-catenin simultaneously, this novel drug molecule will inhibit a number of other relevant targets in prostate cancer (e.g. glucocorticoid and progesterone receptor), and will likely bypass antiandrogen-induced disease resistance.

 
Tagsb-catenin, FKBP51, FKBP52, androgen, androgen receptor, androgen receptor signaling, cancer, cochaperone, glucocorticoid receptor, progesterone receptor, prostate cancer, receptor complex, tumor
 
Posted DateNov 19, 2015 3:45 PM

Researcher

Name
Marc Cox
Artem Cherkasov

Manager

Name
Melissa Silverstein

Advantages

  • Treating castration-resistant prostate cancer
  • Targeting an alternative surface on AR or a novel AR co-regulatory protein
  • Bypassing partial agonistic effects from targeting the hormone binding pocket

Potential Applications

  • Prostate cancer treatment including castration-resistance
  • Inhibition of androgen, glucocorticoid, progesterone receptor signaling

Contact Information

For more information, please contact UTEP's Office of Technology Transfer at techtransfer@utep.edu or 915-747-8030

Files

File Name Description
2014-009 One Pager None Download

Intellectual Property

Patent Number Issue Date Type Country of Filing
PCT/US15/046187 Oct 14, 2014 Other Patent Not Applicable (PCT App)